Evidence map›Paper›PMID 28524077›Full record

ArticleMolecules (Basel, Switzerland)2017

Highly Stereoselective Synthesis of a Compound Collection Based on the Bicyclic Scaffolds of Natural Products.

Murali Annamalai, Stanimira Hristeva, Martyna Bielska, Raquel Ortega, Kamal Kumar

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Murali AnnamalaiMax-Planck-Institut für molekulare Physiologie, Otto-Hahn-Straße 11, 44227 Dortmund, Germany. Murali.Annamalai@mpi-dortmund.mpg.de.
Stanimira HristevaMedicinal Chemistry, Taros Chemicals GmbH & Co. KG, Emil Figge-Str. 76a, 44227 Dortmund, Germany. shristeva@taros.de.
Martyna BielskaMedicinal Chemistry, Taros Chemicals GmbH & Co. KG, Emil Figge-Str. 76a, 44227 Dortmund, Germany. mbielska@taros.de.
Raquel OrtegaMedicinal Chemistry, Taros Chemicals GmbH & Co. KG, Emil Figge-Str. 76a, 44227 Dortmund, Germany. rortega@taros.de.
Kamal KumarMax-Planck-Institut für molekulare Physiologie, Otto-Hahn-Straße 11, 44227 Dortmund, Germany. kamal.kumar@mpi-dortmund.mpg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the great contribution of natural products in the history of successful drug discovery, there are significant limitations that persuade the pharmaceutical industry to evade natural products in drug discovery research. The extreme scarcity as well as structural complexity of natural products renders their practical synthetic access and further modifications extremely challenging. Although other alternative technologies, particularly combinatorial chemistry, were embraced by the pharmaceutical industry to get quick access to a large number of small molecules with simple frameworks that often lack three-dimensional complexity, hardly any success was achieved in the discovery of lead molecules. To acquire chemotypes beholding structural features of natural products, for instance high

Indexed as

Drug DiscoveryBiological ProductsBridged Bicyclo Compounds, HeterocyclicCycloaddition ReactionDrug DesignMolecular StructureSmall Molecule LibrariesStereoisomerismBiological ProductsBridged Bicyclo Compounds, HeterocyclicSmall Molecule LibrariesAza-heterocyclesdrug discoveryEuropean Lead Factorynatural productsscaffolds

Identifiers

PMID28524077
PMCPMC6153746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.